Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Malignant neoplasms evolve in response to changes in oncogenic signalling. Cancer cell plasticity in response to evolutionary pressures is fundamental to tumour progression and the development of therapeutic resistance. Here we determine the molecular and cellular mechanisms of cancer cell plasticity in a conditional oncogenic Kras mouse model of pancreatic ductal adenocarcinoma (PDAC), a malignancy that displays considerable phenotypic diversity and morphological heterogeneity. In this model, stochastic extinction of oncogenic Kras signalling and emergence of Kras-independent escaper populations (cells that acquire oncogenic properties) are associated with de-differentiation and aggressive biological behaviour. Transcriptomic and functional analyses of Kras-independent escapers reveal the presence of Smarcb1-Myc-network-driven mesenchymal reprogramming and independence from MAPK signalling. A somatic mosaic model of PDAC, which allows time-restricted perturbation of cell fate, shows that depletion of Smarcb1 activates the Myc network, driving an anabolic switch that increases protein metabolism and adaptive activation of endoplasmic-reticulum-stress-induced survival pathways. Increased protein turnover renders mesenchymal sub-populations highly susceptible to pharmacological and genetic perturbation of the cellular proteostatic machinery and the IRE1-α-MKK4 arm of the endoplasmic-reticulum-stress-response pathway. Specifically, combination regimens that impair the unfolded protein responses block the emergence of aggressive mesenchymal subpopulations in mouse and patient-derived PDAC models. These molecular and biological insights inform a potential therapeutic strategy for targeting aggressive mesenchymal features of PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior studies using inducible suppression of KRAS via RNA interference or genetically engineered inducible KrasG12D alleles (i.e., “iKras” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRASG12D suppression (35–38).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, studies of the iKras mouse model have highlighted myriad mechanisms to enable bypass of oncogenic KRAS addiction, including the adoption of a KRAS-independent cell state dependent on oxidative phosphorylation (5), induction of SMARCB–MYC-network-driven mesenchymal reprogramming (38), activation of the TGFβ-SMAD3/4 axis via TME remodeling (39), and USP21-mediated upregulation of macrop”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
Self-citationUrano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., & Ron, D. (2000) · Science · doi:10.1126/science.287.5453.664 · Cited by 2,988
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationEMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136 · cited 1×
“The prominent cellular plasticity of PDAC has fueled speculation that these properties may contribute to its aggressive clinical behaviour 4–6 .”
Self-citationSubtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Research works printed but not linked: 1
- Lee, C. L. et al. Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. Dis. Model. Mech. 5, 397–402 (2012)
Cited by
Endoplasmic reticulum stress signals in the tumour and its microenvironment
Chen, X., & Cubillos-Ruiz, J. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00312-2 · Cited by 1,356
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Self-citationRNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues
Yizhak, K., Aguet, F., Kim, J., Hess, J. M., Kübler, K., Grimsby, J., Frazer, R., Zhang, H., Haradhvala, N. J., Rosebrock, D., et al. (2019) · Science · doi:10.1126/science.aaw0726 · Cited by 500
Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0015 · Cited by 455
Andricovich, J., Perkail, S., Kai, Y., Casasanta, N., Peng, W., & Tzatsos, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.003 · Cited by 320
“No changes were observed in the global levels of H3K27me3, H3K27ac, H3K4me1, EZH2, other COMPASS complex members, nor in the Snf5/Smarcb1 tumor suppressor which loss was associated with the transition to QM-squamous histology (Genovese et al., 2017) (Figure S2B and data not shown).”
BackgroundHosein, A. N., Huang, H., Wang, Z., Parmar, K., Du, W., Huang, J., Maitra, A., Olson, E., Verma, U., & Brekken, R. A. (2019) · JCI Insight · doi:10.1172/jci.insight.129212 · Cited by 302
Self-citationNakayama, R. T., Pulice, J. L., Valencia, A. M., McBride, M. J., McKenzie, Z. M., Gillespie, M. A., Ku, W. L., Teng, M., Cui, K., Williams, R. T., et al. (2017) · Nature Genetics · doi:10.1038/ng.3958 · Cited by 291
Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
Avril, T., Vauléon, E., & Chevet, E. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.72 · Cited by 277
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“…of KRAS via RNA interference or genetically engineered inducible Kras G12D alleles (i.e., “ iKras ” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRAS G12D suppression (35–38).”
BackgroundSelf-citationTranslational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 250
Self-citationTP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma
Somerville, T. D. D., Xu, Y., Miyabayashi, K., Tiriac, H., Cleary, C. R., Maia-Silva, D., Milazzo, J. P., Tuveson, D. A., & Vakoc, C. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.051 · Cited by 225
Zwicker, J. I., Schlechter, B. L., Stopa, J. D., Liebman, H. A., Aggarwal, A., Puligandla, M., Caughey, T., Bauer, K. A., Kuemmerle, N., Wong, E., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125851 · Cited by 177
Msaouel, P., Malouf, G. G., Su, X., Yao, H., Tripathi, D. N., Soeung, M., Gao, J., Rao, P., Coarfa, C., Creighton, C. J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2020.04.002 · Cited by 156
Self-citationAcquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 178
IRE1α RNase–dependent lipid homeostasis promotes survival in Myc-transformed cancers
Xie, H., Tang, C.-H. A., Song, J. H., Mancuso, A., Del Valle, J. R., Cao, J., Xiang, Y., Dang, C. V., Lan, R., Sanchez, D. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95864 · Cited by 131
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity
Salvagno, C., Mandula, J. K., Rodríguez, P. C., & Cubillos‐Ruiz, J. R. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.006 · Cited by 144
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 147
The gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 136
Lineage Plasticity in Cancer Progression and Treatment
Magnen, C. L., Shen, M. M., & Abate-Shen, C. T. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050224 · Cited by 116
Terai, H., Kitajima, S., Potter, D. S., Matsui, Y., Quiceno, L. G., Chen, T., Kim, T.-J., Rusan, M., Thai, T. C., Piccioni, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1904 · Cited by 107
Msaouel, P., Hong, A. L., Mullen, E. A., Atkins, M. B., Walker, C. L., Lee, C., Carden, M. A., Genovese, G., Linehan, W. M., Rao, P., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.09.005 · Cited by 106
Self-citationSchmitt, M. J., Company, C., Dramaretska, Y., Barozzi, I., Göhrig, A., Kertalli, S., Großmann, M., Naumann, H., Sanchez-Bailon, M. P., Hulsman, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0219 · Cited by 92
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“Moreover, aggressive mesenchymal subpopulations have been shown to arise through Smarcb1-Myc-network-driven reprogramming upon extinction of KrasG12D expression in animal models of PDAC (Genovese et al. 2017).”
Backgroundp53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Carugo, A., Minelli, R., Sapio, L., Soeung, M., Carbone, F., Robinson, F. S., Tepper, J., Chen, Z., Lovisa, S., Svelto, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.006 · Cited by 97
Self-citationWang, W., Friedland, S. C., Guo, B., O’Dell, M. R., Alexander, W. B., Whitney-Miller, C. L., Agostini-Vulaj, D., Huber, A. R., Myers, J. R., Ashton, J. M., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315541 · Cited by 88
Inhibition of MYC by the SMARCB1 tumor suppressor
Weissmiller, A. M., Wang, J., Lorey, S. L., Howard, G. C., Martinez, E., Liu, Q., & Tansey, W. P. (2019) · Nature Communications · doi:10.1038/s41467-019-10022-5 · Cited by 86
SWI/SNF component ARID1A restrains pancreatic neoplasia formation
Wang, S. C., Nassour, I., Xiao, S., Zhang, S., Luo, X., Lee, J., Li, L., Sun, X., Nguyen, L. H., Chuang, J.-C., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315490 · Cited by 85
Self-citationSeth, S., Li, C.-Y., Ho, I.-L., Corti, D., Loponte, S., Sapio, L., Del Poggetto, E., Yen, E.-Y., Robinson, F. S., Peoples, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.048 · Cited by 84
Self-citationSMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities
Cooper, G. W., & Hong, A. L. (2022) · Cancers · doi:10.3390/cancers14153645 · Cited by 95
Gharibi, A., Kim, S. L., Molnar, J., Brambilla, D., Adamian, Y., Hoover, M. Y., Hong, J., Lin, J., Wolfenden, L., & Kelber, J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-09946-z · Cited by 88
Walczak, A., Gradzik, K., Kabziński, J., Przybyłowska-Sygut, K., & Majsterek, I. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5729710 · Cited by 89
MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
Zhang, T., Li, N., Sun, C., Jin, Y., & Sheng, X. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911845 · Cited by 94
Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77
Tumor microenvironmental nutrients, cellular responses, and cancer
Lobel, G. P., Jiang, Y., & Simon, M. C. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.08.011 · Cited by 88
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 99
Evan, T., Wang, V. M.-Y., & Behrens, A. (2022) · Oncogene · doi:10.1038/s41388-022-02448-x · Cited by 77
The Spatial and Genomic Hierarchy of Tumor Ecosystems Revealed by Single-Cell Technologies
Smith, E. A., & Hodges, H. C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.05.009 · Cited by 64
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma
Jiang, T., Pan, Y., Wan, Z., Lin, Y., Zhu, B., Yuan, Z.-G., Ma, Y., Shi, Y., Zeng, T., Dong, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay0152 · Cited by 65
Self-citationKandimalla, R., Tomihara, H., Banwait, J. K., Yamamura, K., Singh, G. P., Baba, H., & Goel, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4044 · Cited by 57
Tomihara, H., Carbone, F., Perelli, L., Huang, J. K.-L., Soeung, M., Rose, J. L., Robinson, F. S., Lissanu, Y., Feng, N., Takeda, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3922 · Cited by 66
Self-citationFunctional antagonism of chromatin modulators regulates epithelial-mesenchymal transition
Serresi, M., Kertalli, S., Li, L., Schmitt, M. J., Dramaretska, Y., Wierikx, J., Hulsman, D., & Gargiulo, G. (2021) · Science Advances · doi:10.1126/sciadv.abd7974 · Cited by 52
Self-citationLineage Plasticity: The New Cancer Hallmark on the Block
Mehta, A., & Stanger, B. Z. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1067 · Cited by 60
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
Hong, A. L., Tseng, Y.-Y., Wala, J. A., Kim, W.-J., Kynnap, B. D., Doshi, M. B., Kugener, G., Sandoval, G. J., Howard, T. P., Li, J., et al. (2019) · eLife · doi:10.7554/elife.44161 · Cited by 53
Self-citationMcCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49
“Depletion of Smarcb1 activated the Myc network which resulted in an anabolic shift which resulted in increased protein metabolism and activation of ER stress and unfolded protein response [176].”
BackgroundHDAC2 Facilitates Pancreatic Cancer Metastasis
Krauß, L., Urban, B. C., Hastreiter, S., Schneider, C., Wenzel, P., Hassan, Z., Wirth, M., Lankes, K., Terrasi, A., Klement, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3209 · Cited by 55
Evolutionary fingerprints of epithelial-to-mesenchymal transition
Perelli, L., Zhang, L., Mangiameli, S. M., Giannese, F., Mahadevan, K. K., Peng, F., Citron, F., Khan, H., Le, C. N., Gurreri, E., et al. (2025) · Nature · doi:10.1038/s41586-025-08671-2 · Cited by 55
Self-citationBehind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 43
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 43
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma
Wilson, N. R., Wiele, A. J., Surasi, D. S., Rao, P., Sircar, K., Tamboli, P., Shah, A. Y., Genovese, G., Karam, J. A., Wood, C. G., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.08.007 · Cited by 41
Self-citationEmerging Themes in Mechanisms of Tumorigenesis by SWI/SNF Subunit Mutation
Jones, C. A., Tansey, W. P., & Weissmiller, A. M. (2022) · Epigenetics Insights · doi:10.1177/25168657221115656 · Cited by 40
The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?
Loponte, S., Lovisa, S., Deem, A. K., Carugo, A., & Viale, A. (2019) · Cancers · doi:10.3390/cancers11101574 · Cited by 38
Self-citationFraunhoffer, N. A., Abuelafia, A. M., Bigonnet, M., Gayet, O., Roques, J., Telle, E., Santofimia‐Castaño, P., Borrello, M. T., Chuluyán, E., Dusetti, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1232 · Cited by 39
The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma
Tsuda, M., Fukuda, A., Kawai, M., Araki, O., & Seno, H. (2020) · Cancer Science · doi:10.1111/cas.14768 · Cited by 38
Perelli, L., Carbone, F., Zhang, L., Huang, J. K.-L., Le, C. N., Khan, H., Citron, F., Poggetto, E. D., Gutschner, T., Tomihara, H., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00584-1 · Cited by 37
Self-citationWoodley, C. M., Romer, A. S., Wang, J., Guarnaccia, A. D., Elion, D. L., Maxwell, J. N., Guerrazzi, K., McCann, T. S., Popay, T. M., Matlock, B. K., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01804-7 · Cited by 33
Ruta, V., Naro, C., Pieraccioli, M., Leccese, A., Archibugi, L., Cesari, E., Panzeri, V., Allgöwer, C., Arcidiacono, P. G., Falconi, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101411 · Cited by 39
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome
Martino, S. D., Amoreo, C. A., Nuvoli, B., Galati, R., Strano, S., Facciolo, F., Alessandrini, G., Pass, H. I., Ciliberto, G., Blandino, G., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0044-8 · Cited by 29
Gurreri, E., Genovese, G., Perelli, L., Agostini, A., Piro, G., Carbone, C., & Tortora, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119313 · Cited by 32
Self-citationSmarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
Ferguson, L. P., Gatchalian, J., McDermott, M. L., Nakamura, M., Chambers, K. R., Rajbhandari, N., Lytle, N. K., Rosenthal, S. B., Hamilton, M., Albini, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35796-7 · Cited by 29
Dai, J., Jiang, M., Hu, Y., Xiao, J., Hu, B., Xu, J., Han, X., Shen, S., Ли, Б., Wu, Z., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.138584 · Cited by 27
Sato, K., Hikita, H., Myojin, Y., Fukumoto, K., Murai, K., Sakane, S., Tamura, T., Yamai, T., Nozaki, Y., Yoshioka, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235573 · Cited by 29
Academic Discovery of Anticancer Drugs: Historic and Future Perspectives
Carugo, A., & Draetta, G. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055645 · Cited by 30
Self-citationZheng, X., Liu, X., Zheng, H., Wang, H., & Hong, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106982 · Cited by 24
Self-citationYoneda, A., Minomi, K., & Tamura, Y. (2021) · Cancer Science · doi:10.1111/cas.14976 · Cited by 25
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
Zhang, Y., Liang, S., Saliakoura, M., Yang, H., Vassella, E., Konstantinidou, G., Tschan, M. P., Hegedűs, B., Zhao, L., Gao, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013193 · Cited by 25
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 25
Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis
Ferri-Borgogno, S., Barui, S., McGee, A. M., Griffiths, T., Singh, P. K., Piett, C. G., Ghosh, B., Bhattacharyya, S., Singhi, A., Pradhan, K., et al. (2020) · Cancers · doi:10.3390/cancers12092695 · Cited by 22
“In this context, while MYC is considered a downstream effector of oncogenic Ras in PDAC, mediating its pleiotropic effects on tumor cell growth and metabolism [40,41], MYC can also substitute as a pivotal driver in the setting of “Ras independence”, and the resulting tumors tend to be highly aggressive and chemoresist…”
BackgroundSelf-citationTargeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC
Lankes, K., Hassan, Z., Doffo, J., Schneeweis, C., Lier, S., Öllinger, R., Rad, R., Krämer, O. H., Keller, U. B., Saur, D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12835 · Cited by 23
Metabolic Constrains Rule Metastasis Progression
Roda, N., Gambino, V., & Giorgio, M. (2020) · Cells · doi:10.3390/cells9092081 · Cited by 23
The many faces of cancer evolution
Ciriello, G., & Magnani, L. (2021) · iScience · doi:10.1016/j.isci.2021.102403 · Cited by 22
Martinez-Turtos, A., Paul, R., Grima-Reyes, M., Issaoui, H., Krug, A., Mhaidly, R., Bossowski, J. P., Chiche, J., Marchetti, S., Verhoeyen, E., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2116844 · Cited by 22
Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
Florian, A. C., Woodley, C. M., Wang, J., Grieb, B. C., Slota, M. J., Guerrazzi, K., Hsu, C., Matlock, B. K., Flaherty, D. K., Lorey, S. L., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac007 · Cited by 19
Cancer as a Disease of Development Gone Awry
Stanger, B. Z., & Wahl, G. M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-025610 · Cited by 27
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy
Shapiro, D. D., Zacharias, N. M., Tripathi, D. N., Karki, M., Bertocchio, J., Soeung, M., He, R. L., Westerman, M. E., Gao, J., Rao, P., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1267 · Cited by 21
Self-citationMolecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye
Msaouel, P., Walker, C. L., Genovese, G., & Tannir, N. M. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1777060 · Cited by 19
Self-citationEmerging Role of CREB in Epithelial to Mesenchymal Plasticity of Pancreatic Cancer
Mehra, S., Singh, S. P., & Nagathihalli, N. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925687 · Cited by 19
Qian, Y., Gong, Y., Zou, X., Liu, Y., Chen, Y., Wang, R., Dai, Z., Tasiheng, Y., Lin, X., Wang, X., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00411-9 · Cited by 26
Self-citationNovel therapy for pediatric and adolescent kidney cancer
Walz, A. L., Fernandez, C. V., & Geller, J. I. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09822-4 · Cited by 17
Moe, K. C., Maxwell, J. N., Wang, J., Jones, C. A., Csaki, G. T., Florian, A. C., Romer, A. S., Bryant, D. L., Farone, A. L., Liu, Q., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00406-6 · Cited by 17
Acquired resistance to molecularly targeted therapies for cancer
Stubbs, N. M., Roady, T. J., Schwermann, M. P., Eteshola, E. O. U., MacDonald, W., Purcell, C., Ryspayeva, D., Verovkina, N., Tajiknia, V., Ghandali, M., et al. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.189 · Cited by 41
Kawai, M., Fukuda, A., Ikeda, M., Iimori, K., Mizukoshi, K., Iwane, K., Yamakawa, G., Omatsu, M., Namikawa, M., Sono, M., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci177533 · Cited by 14
ER stress and/or ER-phagy in drug resistance? Three coincidences are proof
Panda, S. K., Sanchez-Pajares, I. R., Rehman, A., Vecchio, V. D., Mele, L. L., Chipurupalli, S., Robinson, N., & Desiderio, V. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02232-w · Cited by 13
Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series
Ryan, A., Tawagi, K., VanderVeen, N. T., Matrana, M. R., & Vasquez, R. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.08.004 · Cited by 12
The KRAS mutational spectrum and its clinical implications in pancreatic cancer
Perelli, L., Genovese, G., & Draetta, G. F. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.001 · Cited by 13
Self-citationOncogenic signaling pathways in pancreatic ductal adenocarcinoma
Agrawal, R., & Natarajan, K. N. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.006 · Cited by 11
The unfolded protein response links ER stress to cancer-associated thrombosis
Muse, O., Patell, R. D., Peters, C. G., Yang, M., El-Darzi, E., Schulman, S., Falanga, A., Marchetti, M., Russo, L., Zwicker, J. I., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170148 · Cited by 11
Kotagiri, S., Wang, Y., Han, Y., Liang, X., Blazanin, N., Mazhar, H., Sebastian, M. M., Nguyen, P. K., Jiang, Y., & Lissanu, Y. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02577 · Cited by 14
Reg4 regulates pancreatic regeneration following pancreatitis via modulating the Notch signaling
Dai, J., He, Y., Jiang, M., Niu, M., Li, B., Wu, Z., Bao, J., Li, W., Wang, X., & Hu, G. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30397 · Cited by 10
Liang, M., Li, J. W., Luo, H., Lulu, S., Calbay, O., Shenoy, A. K., Tan, M., Law, B. K., Huang, S., Xiao, T. S., et al. (2022) · Cells · doi:10.3390/cells11142208 · Cited by 12
Mugaanyi, J., Lu, C., Lu, C., & Wang, C. (2021) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2021.105938 · Cited by 8
Akimov, Y. A., Bulanova, D. R., Abyzova, M. S., Wennerberg, K., & Aittokallio, T. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622506 · Cited by 7
Nguyen, A., Mustafa, A. M., Leydecker, A. K., Halilovic, M., Murr, J., Butter, F., & Krämer, O. H. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01597-8 · Cited by 8
Oncogenic dependency plays a dominant role in the immune response to cancer
Li, J., D’Amico, S., Kirillov, V., Petrenko, O., & Reich, N. C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308635120 · Cited by 6
Dedifferentiation of Epithelial Cells Incorporates Immune Reprogramming
Ma, Y., & Hao, J. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.01.007 · Cited by 6
Lin, T.-C., Liao, Y., Chang, W., Yang, C.-H., Cheng, L.-H., Cheng, M., & Cheng, H.-C. (2018) · Journal of Visualized Experiments · doi:10.3791/56761 · Cited by 8
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 10
Surgical and oncological management of renal medullary carcinoma in a young patient: a case report
Courcier, J., TAILLE, A. D. L., Bertolo, R. G., Amparore, D., Erdem, S., Kara, Ö., Marchioni, M., Pavan, N., Roussel, E., Mamodaly, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1073728 · Cited by 5
Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J., & Choi, W. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_14 · Cited by 5
Evolutionary fingerprints of EMT in pancreatic cancersPreprint
Perelli, L., Zhang, L., Mangiameli, S. M., Russell, A. J. C., Giannese, F., Peng, F., Carbone, F., Le, C. N., Khan, H., Citron, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.18.558231 · Cited by 4
Self-citation
Metadata
- Authors
- Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., Gutschner, T., Wu, C.-C., Seth, S., Akdemir, K. C., Leo, E., Amin, S., Molin, M. D., Ying, H., Kwong, L. N., Colla, S., Takahashi, K., Ghosh, P., Giuliani, V., Muller, F., Dey, P., Jiang, S., Garvey, J., Liu, C.-G., Zhang, J., Heffernan, T. P., Toniatti, C., Fleming, J. B., Goggins, M. G., Wood, L. D., Sgambato, A., Agaimy, A., Maitra, A., Roberts, C. W. M., Wang, H., Viale, A., DePinho, R. A., Draetta, G. F., & Chin, L.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Università Cattolica del Sacro Cuore (IT)
- Johns Hopkins University (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- St. Jude Children's Research Hospital (US)
- Corresponding author
- Genovese, Giannicola
- Draetta, Giulio F.
- ORCID
- Genovese, Giannicola
- Carugo, Alessandro
- Robinson, Frederick Scott
- Svelto, Maria
- Nezi, Luigi
- Corti, Denise
- Pettazzoni, Piergiorgio
- Gutschner, Tony
- Wu, Chia-Chin
- Seth, Sahil
- Akdemir, Kadir Caner
- Leo, Elisabetta
- Amin, Samirkumar
- Molin, Marco Dal
- Ying, Haoqiang
- Kwong, Lawrence N.
- Colla, Simona
- Takahashi, Koichi
- Giuliani, Virginia
- Dey, Prasenjit
- Jiang, Shan
- Zhang, Jianhua
- Heffernan, Timothy P.
- Toniatti, Carlo
- Fleming, Jason B.
- Goggins, Michael G.
- Wood, Laura D.
- Sgambato, Alessandro
- Agaimy, Abbas
- Maitra, Anirban
- Roberts, Charles W. M.
- Wang, Huamin
- Viale, Andrea
- DePinho, Ronald A.
- Draetta, Giulio F.
- Venue
- Nature
- Published
- 2017-02-08
- Volume
- 542
- Issue
- 7641
- Pages
- 362-366
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7609022
- OpenAlex
- W2586537166
- Cited by
- 131
- References
- 58
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 8 · 2023: 16 · 2022: 14 · 2021: 15 · 2020: 17 · 2019: 17 · 2018: 11 · 2017: 11
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-08-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R00CA218891, U01CA141508, K99CA218891, P50CA062924, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, SMARCB1, tumor plasticity, protein metabolism, endoplasmic reticulum stress response, unfolded protein response, MAPK signaling, dedifferentiation, proteostasis
- MeSH terms
- SMARCB1 Protein, Gemcitabine, Animals, Deoxycytidine, Female, Humans, Male, Mesoderm, Mosaicism, Pancreatic Neoplasms, Genes, ras, Genes, myc, Oncogene Protein p55(v-myc), Proto-Oncogene Proteins p21(ras), MAP Kinase Signaling System, Carcinoma, Pancreatic Ductal, MAP Kinase Kinase 4, Mice, Transcriptome, Proteolysis, Endoplasmic Reticulum Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.